| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Internal Medicine, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75235-8887
Mevalonate is the precursor of a number of different products potentially required for the growth of cells, including the prenylated oncoprotein Ras. To determine whether inhibition of mevalonate metabolism would selectively block proliferation of Ras-transformed cells, 6-fluoromevalonate (Fmev), an inhibitor of diphosphomevalonate decarboxylase, was used to block the synthesis of prenyl-derived lipids and prenylated proteins in interleukin-3 (IL-3)-dependent FDC-P1 cells (control FDC-P1 cells) and FDC-P1 cells transformed with oncogenic Ras (RasDC cells) that proliferated in the absence of IL-3. Fmev completely inhibited synthesis of prenyl-derived lipids and prenylated proteins and blocked proliferation of FDC-P1 and RasDC cells. Restoration of the proliferation of Fmev-blocked FDC-P1 cells required both an exogenous source of cholesterol and prevention of the accumulation of mevalonate and the mevalonate phosphates with lovastatin. In contrast, ongoing IL-3-independent proliferation of Fmev-blocked RasDC cells was not completely restored by providing exogenous cholesterol and preventing the accumulation of inhibitory mevalonate product(s). However, these cells proliferated when cultures were supplemented with IL-3 together with exogenous cholesterol and lovastatin, implying that Fmev had prevented Ras-dependent, IL-3-independent growth. Fmev markedly diminished total cellular Ras in RasDC cells. In contrast, lovastatin depleted membrane-associated Ras and increased cytosolic Ras but did not diminish total cellular Ras. These data indicate that Fmev depletes total cellular Ras and specifically inhibits the autonomous growth of Ras-transformed cells.
1 This work was supported by Grant CN-108 from the American Cancer Society and Public Health Service Grant AI-17653 from the NIH.
2 To whom requests for reprints should be addressed, at Liver Unit, Department of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75235-8887.
Received 12/27/94. Accepted 2/13/95.
This article has been cited by other articles:
![]() |
J. Oberdoerster, M. Guizzetti, and L. G. Costa Effect of Phenylalanine and Its Metabolites on the Proliferation and Viability of Neuronal and Astroglial Cells: Possible Relevance in Maternal Phenylketonuria J. Pharmacol. Exp. Ther., October 1, 2000; 295(1): 295 - 301. [Abstract] [Full Text] |
||||
![]() |
R. S. J. Makar, P. E. Lipsky, and J. A. Cuthbert Sterol-independent, sterol response element-dependent, regulation of low density lipoprotein receptor gene expression J. Lipid Res., August 1, 1998; 39(8): 1647 - 1654. [Abstract] [Full Text] |
||||
![]() |
B. M. Forman, B. Ruan, J. Chen, G. J. Schroepfer Jr., and R. M. Evans The orphan nuclear receptor LXRalpha is positively and negatively regulated by distinct products of mevalonate metabolism PNAS, September 30, 1997; 94(20): 10588 - 10593. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. He, H. Mo, S. Hadisusilo, A. A. Qureshi, and C. E. Elson Isoprenoids Suppress the Growth of Murine B16 Melanomas In Vitro and In Vivo J. Nutr., May 1, 1997; 127(5): 668 - 674. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Toth and L. Huwyler Molecular Cloning and Expression of the cDNAs Encoding Human and Yeast Mevalonate Pyrophosphate Decarboxylase J. Biol. Chem., April 5, 1996; 271(14): 7895 - 7898. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |